Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An open, randomised phase I/II dose escalation study evaluating the safety and tolerability, pharmacokinetics, antigenicity and efficacy of iodine-131-Kab201 [anti-CEA monoclonal antibody I-131] when given intra-arterially or intravenously in patients with surgically unresectable pancreatic ductal adenocarcinoma.

Next Previous
X
Search
Trial Profile

An open, randomised phase I/II dose escalation study evaluating the safety and tolerability, pharmacokinetics, antigenicity and efficacy of iodine-131-Kab201 [anti-CEA monoclonal antibody I-131] when given intra-arterially or intravenously in patients with surgically unresectable pancreatic ductal adenocarcinoma.

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 14 May 2009

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs XR 303 (Primary) ; XR 303 (Primary)
  • Indications Pancreatic cancer
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Acronyms KaBI
  • Sponsors Xenova Group

    • Most Recent Events

    • 12 May 2009 Additional location identified as reported by Current Controlled Trials.
    • 12 May 2009 Additional lead trial centre identified as reported by Current Controlled Trials.
    • 12 May 2009 Status changed from not stated to completed as reported by Current Controlled Trials

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top